Data from a 6-year analysis of the APHINITY trial showed that adding pertuzumab to the previous standard of trastuzumab plus chemotherapy after surgery continued to reduce the risk of recurrence and death in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. There were fewer deaths in patients treated with pertuzumab, although the survival benefit was not statistically significant at this time.
In its primary analysis, the APHINITY trial demonstrated that pertuzumab when added to adjuvant trastuzumab and chemotherapy statistically significantly (although modestly) improved invasive disease-free survival (iDFS) among patients with HER2-positive, operable breast cancer . Between November 2011 and August 2013, a total of 2,400 patients were randomly assigned to receive pertuzumab whilst 2,404 patients received placebo . The median follow-up was 45.4 months. In the intention-to-treat (ITT) population, the estimate...
Please login to read the full text of the article.
If you have no account yet, please register now.
« High rates of ROR-low disease with chemotherapy-free regimen in HR+/HER2- patients Next Article
S-1 shows promising results in combination with endocrine therapy »